August 2, 2017
CTI BioPharma completes enrollment in the Phase 3 trial of aggressive B-cell non-Hodgkin lymphoma drug
CTI BioPharma has completed enrollment in the Phase 3 PIX306 trial of PIXUVRI (pixantrone).
Pharmaceuticals, Biotechnology and Life Sciences
Tag: PIXUVRI (pixantrone)